These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 18550587)

  • 1. Acquired factor VIII and von Willebrand factor (aFVIII/VWF) deficiency and hypothyroidism in a case with hypopituitarism.
    Oliveira MC; Kramer CK; Marroni CP; Leães CG; Viana L; Roithman S; Schmaedecke A; Pereira-Lima JF
    Clin Appl Thromb Hemost; 2010 Feb; 16(1):107-9. PubMed ID: 18550587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acquired von Willebrand's syndrome associated with decrease of plasminogen activator and its inhibitor during hypothyroidism.
    Levesque H; Borg JY; Cailleux N; Vasse M; Daliphard S; Gancel A; Monconduit M; Courtois H
    Eur J Med; 1993 May; 2(5):287-8. PubMed ID: 8252160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factor VIII-von Willebrand factor binding defects in autosomal recessive von Willebrand disease type Normandy and in mild hemophilia A. New insights into factor VIII-von Willebrand factor interactions.
    Jacquemin M
    Acta Haematol; 2009; 121(2-3):102-5. PubMed ID: 19506355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1.
    Michiels JJ; Gadisseur A; Vangenegten I; Schroyens W; Berneman Z
    Acta Haematol; 2009; 121(2-3):119-27. PubMed ID: 19506358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acquired von Willebrand syndrome in patients with overt hypothyroidism: a prospective cohort study.
    Stuijver DJ; Piantanida E; van Zaane B; Galli L; Romualdi E; Tanda ML; Meijers JC; Büller HR; Gerdes VE; Squizzato A
    Haemophilia; 2014 May; 20(3):326-32. PubMed ID: 24118466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Acquired von Willebrand syndrome with autoimmune hemolytic anemia].
    Ishimaru F; Hayashi H; Fujita T; Tsurumi N; Tsuda T; Kimura I
    Rinsho Ketsueki; 1990 Sep; 31(9):1493-8. PubMed ID: 2246822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management.
    Michiels JJ; Budde U; van der Planken M; van Vliet HH; Schroyens W; Berneman Z
    Best Pract Res Clin Haematol; 2001 Jun; 14(2):401-36. PubMed ID: 11686107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Acquired von Willebrand syndrome].
    de Lange DW; Fijnheer R; Wittebol S
    Ned Tijdschr Geneeskd; 2003 Sep; 147(37):1808-11. PubMed ID: 14526622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease.
    Budde U; Metzner HJ; Müller HG
    Semin Thromb Hemost; 2006 Sep; 32(6):626-35. PubMed ID: 16977573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
    Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DDAVP infusion in haemophilia A carriers: different behaviour of plasma factor VIII and von Willebrand factor.
    Casonato A; Dannhauser D; Pontara E; Bertomoro A; Orazi B; Santarossa L; Zerbinati P; Girolami A
    Blood Coagul Fibrinolysis; 1996 Jul; 7(5):549-53. PubMed ID: 8874865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulated release of VWF and FVIII and the biologic implications.
    Haberichter SL; Shi Q; Montgomery RR
    Pediatr Blood Cancer; 2006 May; 46(5):547-53. PubMed ID: 16470522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acquired von Willebrand syndrome: diagnostic problems and therapeutic options.
    Eikenboom JC; Tjernberg P; Van Marion V; Heering KJ
    Am J Hematol; 2007 Jan; 82(1):55-8. PubMed ID: 16986130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variant von Willebrand disease with defective binding to factor VIII: the first case from Japan.
    Nishino M; Miura S; Yoshioka A; Kuwahara I; Nishimura T; Hamada K; Fukui H
    Int J Hematol; 1993 Apr; 57(2):163-73. PubMed ID: 8494994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Causes, etiology and diagnosis of acquired von Willebrand disease: a prospective diagnostic workup to establish the most effective therapeutic strategies.
    Sucker C; Michiels JJ; Zotz RB
    Acta Haematol; 2009; 121(2-3):177-82. PubMed ID: 19506364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The factor VIII/von Willebrand factor ratio discriminates between reduced synthesis and increased clearance of von Willebrand factor.
    Eikenboom JC; Castaman G; Kamphuisen PW; Rosendaal FR; Bertina RM
    Thromb Haemost; 2002 Feb; 87(2):252-7. PubMed ID: 11859851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune-mediated etiology of acquired von Willebrand syndrome in systemic lupus erythematosus and in benign monoclonal gammopathy: therapeutic implications.
    Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; Budde U; van Vliet HH
    Semin Thromb Hemost; 2006 Sep; 32(6):577-88. PubMed ID: 16977568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Restoration of plasma von Willebrand factor deficiency is sufficient to correct thrombus formation after gene therapy for severe von Willebrand disease.
    De Meyer SF; Vandeputte N; Pareyn I; Petrus I; Lenting PJ; Chuah MK; VandenDriessche T; Deckmyn H; Vanhoorelbeke K
    Arterioscler Thromb Vasc Biol; 2008 Sep; 28(9):1621-6. PubMed ID: 18556568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The factor VIII/von Willebrand factor complex: basic and clinical issues.
    Federici AB
    Haematologica; 2003 Jun; 88(6):EREP02. PubMed ID: 12826528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.